Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of stereotactic radiosurgery plus camrelizumab in advanced chordoma
ChiCTR2000036415Phase 2Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in chordoma, sponsored by Shanghai Changzheng Hospital. Primary endpoints: Progression-free survival and Objective response rate. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
chordoma
Beyond the preview
Go deeper on ChiCTR2000036415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036415.